Literature DB >> 11810583

Relationship between mutations in the DNA gyrase and topoisomerase IV genes and nadifloxacin resistance in clinically isolated quinolone-resistant Staphylococcus aureus.

N Oizumi1, S Kawabata, M Hirao, K Watanabe, S Okuno, T Fujiwara, M Kikuchi.   

Abstract

We analyzed the relationship between resistance to nadifloxacin, a fluoroquinolone antimicrobial agent, and mutations in the quinolone resistance-determining regions (QRDRs) of the A subunit of DNA gyrase and topoisomerase IV, in 24 clinical isolates of Staphylococcus aureus. Seven known mutations were found in the QRDRs. The minimum inhibitory concentration (MIC) of nadifloxacin increased in a manner that was dependent on mutations in the A subunit of DNA gyrase, and did not appear to be related to mutations in the A subunit of topoisomerase IV. The type 9 mutant, which included four mutations, was highly resistant to ofloxacin, norfloxacin and sparfloxacin, but only moderately resistant to nadifloxacin (MIC, 12.5 microg/ml). One of the norfloxacin-resistant strains that expressed high levels of norA was not resistant to nadifloxacin. To the best of our knowledge, this is the first report describing a fluoroquinolone antimicrobial agent whose primary target is suggested to be DNA gyrase in S. aureus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11810583     DOI: 10.1007/s101560100034

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  8 in total

1.  The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors:  Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria.

Authors:  Laura J V Piddock
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

3.  Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models.

Authors:  Mahesh V Patel; Noel J De Souza; Shrikant V Gupte; Mohammad A Jafri; Sachin S Bhagwat; Yati Chugh; Habil F Khorakiwala; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  In vitro activity of the new quinolone WCK 771 against staphylococci.

Authors:  Michael R Jacobs; Saralee Bajaksouzian; Anne Windau; Peter C Appelbaum; Mahesh V Patel; Shrikant V Gupte; Sachin S Bhagwat; Noel J De Souza; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 5.  Transdermal penetration of topical drugs used in the treatment of acne.

Authors:  Andrea Krautheim; Harald Gollnick
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Resistance of Stenotrophomonas maltophilia to Fluoroquinolones: Prevalence in a University Hospital and Possible Mechanisms.

Authors:  Wei Jia; Jiayuan Wang; Haotong Xu; Gang Li
Journal:  Int J Environ Res Public Health       Date:  2015-05-13       Impact factor: 3.390

Review 7.  Quinolone antibiotics.

Authors:  Thu D M Pham; Zyta M Ziora; Mark A T Blaskovich
Journal:  Medchemcomm       Date:  2019-06-28       Impact factor: 3.597

8.  Efficacy and safety of nadifloxacin for bacterial skin infections: results from clinical and post-marketing studies.

Authors:  Varsha Narayanan; Salman Motlekar; Ganesh Kadhe; Seema Bhagat
Journal:  Dermatol Ther (Heidelb)       Date:  2014-09-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.